Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer

doi:10.1007/978-3-642-28160-0

Cited by 8 publications

(5 citation statements)

References 84 publications

(109 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, miRNAs present advantages that make them interesting to be used as diagnostic tools. These include being stable molecules that can be easily detected in body fluids, such as plasma and the fact that their expression has been correlated with clinicopathological features, being promising as prognostic and predictive biomarkers [9].…”

Section: Discussionmentioning

confidence: 99%

“…Recently, microRNAs (miRNAs) have emerged as new diagnostic and therapeutic biomarkers for BC [3,8,9]. miRNAs are small non-coding RNAs of 19-25 nucleotides in length, which are key regulators of post-transcriptional gene expression through the silencing of messenger RNAs (mRNAs) by different mechanisms [10].…”

Section: Introductionmentioning

confidence: 99%

“…miRNAs are small non-coding RNAs of 19-25 nucleotides in length, which are key regulators of post-transcriptional gene expression through the silencing of messenger RNAs (mRNAs) by different mechanisms [10]. MiRNAs are involved in a wide variety of biological processes, such as proliferation, apoptosis, or cell cycle [9,[11][12][13]. Therefore, the dysregulation of miRNA expression has been shown to have important effects on several diseases, such as autoimmune disorders, bone diseases, or cancer.…”

Section: Introductionmentioning

confidence: 99%

“…MiRNAs are detectable in biological fluids that can be collected with minimal invasive techniques. Thus, the diagnostic and prognostic value of circulating miRNAs might be of great interest [9]. Several studies have been assessing the potential use of circulating miRNAs in plasma as biomarkers for different types of cancers and, nowadays, they are considered promising markers for diagnosis, prognosis, and treatment response [7,[15][16][17][18].…”

Section: Introductionmentioning

confidence: 99%

“…Several studies have been assessing the potential use of circulating miRNAs in plasma as biomarkers for different types of cancers and, nowadays, they are considered promising markers for diagnosis, prognosis, and treatment response [7,[15][16][17][18]. In BC, it has been proven that circulating miRNAs differ between cancer patients and healthy volunteers [9,19,20]. Therefore, miRNAs could be used as effective minimally invasive biomarkers for the diagnosis and monitoring of BC patients.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Circulating miR-99a-5p Expression in Plasma: A Potential Biomarker for Early Diagnosis of Breast Cancer

Garrido‐Cano

Constâncio

Adam‐Artigues

et al. 2020

IJMS

View full text Add to dashboard Cite

MicroRNAs have emerged as new diagnostic and therapeutic biomarkers for breast cancer. Herein, we analysed miR-99a-5p expression levels in primary tumours and plasma of breast cancer patients to evaluate its usefulness as a minimally invasive diagnostic biomarker. MiR-99a-5p expression levels were determined by quantitative real-time PCR in three independent cohorts of patients: (I) Discovery cohort: breast cancer tissues (n = 103) and healthy breast tissues (n = 26); (II) Testing cohort: plasma samples from 105 patients and 98 healthy donors; (III) Validation cohort: plasma samples from 89 patients and 85 healthy donors. Our results demonstrated that miR-99a-5p was significantly downregulated in breast cancer tissues compared to healthy breast tissues. Conversely, miR-99a-5p levels were significantly higher in breast cancer patients than in healthy controls in plasma samples from both testing and validation cohorts, and ROC curve analysis revealed that miR-99a-5p has good diagnostic potential even to detect early breast cancer. In conclusion, miR-99a-5p’s deregulated expression distinguished healthy patients from breast cancer patients in two different types of samples (tissues and plasma). Interestingly, expression levels in plasma were significantly lower in healthy controls than in early-stage breast cancer patients. Our findings suggest circulating miR-99a-5p as a novel promising non-invasive biomarker for breast cancer detection.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Circulating miR-99a-5p Expression in Plasma: A Potential Biomarker for Early Diagnosis of Breast Cancer

Garrido‐Cano

Constâncio

Adam‐Artigues

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

Brief Summary and Perspectives for CTCs

Tarazona

Chinen

2021

Atlas of Liquid Biopsy

View full text Add to dashboard Cite

Nanoporous Anodic Alumina-Based Sensor for miR-99a-5p Detection as an Effective Early Breast Cancer Diagnostic Tool

et al. 2021

View full text Add to dashboard Cite

Circulating microRNAs have emerged as potential diagnostic biomarkers. The deregulation of the microRNA miR-99a-5p has been previously described as an effective biomarker of early breast cancer. Herein, we present a new nanoporous anodic alumina (NAA)-based biosensor that can detect plasma miR-99a-5p with high sensitivity and selectivity. NAA pores are loaded with rhodamine B and capped with a specific oligonucleotide that is able to block cargo release until the target is present. In the presence of miR-99a-5p, the capping oligonucleotide recognizes the miR-99a-5p sequence and displaces it allowing the release of the encapsulated dye. This method is able to successfully distinguish healthy controls from breast cancer patients, even at early stages with high efficiency, showing the presented system as a promising tool for breast cancer detection.

show abstract

Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer

Cited by 8 publications

References 84 publications

Circulating miR-99a-5p Expression in Plasma: A Potential Biomarker for Early Diagnosis of Breast Cancer

Circulating miR-99a-5p Expression in Plasma: A Potential Biomarker for Early Diagnosis of Breast Cancer

Brief Summary and Perspectives for CTCs

Nanoporous Anodic Alumina-Based Sensor for miR-99a-5p Detection as an Effective Early Breast Cancer Diagnostic Tool

Contact Info

Product

Resources

About